Eli Lilly Japan’s 2012 Results Boosted 10.2% By Flagship Drugs Zyprexa, Forteo
This article was originally published in PharmAsia News
Executive Summary
Eli Lilly Japan announced sales results of ¥175.74 billion for fiscal 2012. Results were boosted by the company’s flagship products.